JP2011504736A5 - - Google Patents

Download PDF

Info

Publication number
JP2011504736A5
JP2011504736A5 JP2010535301A JP2010535301A JP2011504736A5 JP 2011504736 A5 JP2011504736 A5 JP 2011504736A5 JP 2010535301 A JP2010535301 A JP 2010535301A JP 2010535301 A JP2010535301 A JP 2010535301A JP 2011504736 A5 JP2011504736 A5 JP 2011504736A5
Authority
JP
Japan
Prior art keywords
pulmonary
pharmaceutical composition
nucleic acid
hypertension
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010535301A
Other languages
English (en)
Japanese (ja)
Other versions
JP5777341B2 (ja
JP2011504736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/010167 external-priority patent/WO2009068318A1/en
Publication of JP2011504736A publication Critical patent/JP2011504736A/ja
Publication of JP2011504736A5 publication Critical patent/JP2011504736A5/ja
Application granted granted Critical
Publication of JP5777341B2 publication Critical patent/JP5777341B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010535301A 2007-11-30 2008-11-29 Mcp−1結合核酸およびその使用 Expired - Fee Related JP5777341B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023267 2007-11-30
EP07023267.3 2007-11-30
PCT/EP2008/010167 WO2009068318A1 (en) 2007-11-30 2008-11-29 Mcp-i binding nucleic acids and use thereof

Publications (3)

Publication Number Publication Date
JP2011504736A JP2011504736A (ja) 2011-02-17
JP2011504736A5 true JP2011504736A5 (enExample) 2015-07-02
JP5777341B2 JP5777341B2 (ja) 2015-09-09

Family

ID=40415282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535301A Expired - Fee Related JP5777341B2 (ja) 2007-11-30 2008-11-29 Mcp−1結合核酸およびその使用

Country Status (12)

Country Link
US (2) US20100311816A1 (enExample)
EP (1) EP2229442A1 (enExample)
JP (1) JP5777341B2 (enExample)
KR (1) KR20100092463A (enExample)
CN (1) CN101878305A (enExample)
AU (1) AU2008329070B2 (enExample)
BR (1) BRPI0819845A2 (enExample)
CA (1) CA2707089A1 (enExample)
MX (1) MX2010005916A (enExample)
RU (1) RU2542973C2 (enExample)
WO (1) WO2009068318A1 (enExample)
ZA (1) ZA201002974B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2135949T3 (pl) 2006-02-14 2013-03-29 Noxxon Pharma Ag Kwasy nukleinowe wiążące MCP-1
CA2707089A1 (en) * 2007-11-30 2009-06-04 Noxxon Pharma Ag Mcp-1 binding nucleic acids and use thereof
WO2012025251A1 (en) 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
CN102621331B (zh) * 2012-04-05 2014-07-30 中国医学科学院病原生物学研究所 一种检测或辅助检测结核性胸膜炎的试剂盒
EP3065744B1 (en) * 2013-11-04 2021-04-21 Noxxon Pharma AG A ccl2 antagonist for use in treating proteinuria

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
EP1438321B1 (de) * 2001-10-26 2010-05-26 Noxxon Pharma AG Modifizierte l-nukleinsäure
US7879991B2 (en) * 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
EP1530635B1 (en) * 2002-08-01 2011-06-15 Noxxon Pharma AG Ghrelin binding nucleic acids
AU2004231087B2 (en) * 2003-04-15 2007-01-04 Merck Sharp & Dohme Corp. Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
EP1732571A4 (en) * 2004-03-05 2009-09-09 Archemix Corp CONTROLLED MODULATION OF PHARMACOKINETICS AND BIODISTRIBUTION OF APTAMER THERAPEUTICS
US20060257359A1 (en) * 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
PL2135949T3 (pl) * 2006-02-14 2013-03-29 Noxxon Pharma Ag Kwasy nukleinowe wiążące MCP-1
CA2707089A1 (en) * 2007-11-30 2009-06-04 Noxxon Pharma Ag Mcp-1 binding nucleic acids and use thereof

Similar Documents

Publication Publication Date Title
CY1125006T1 (el) Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια
JP2014526441A5 (enExample)
JP2015518818A5 (enExample)
JP2010222367A5 (enExample)
JP2011528333A5 (enExample)
JP2019526611A5 (enExample)
WO2009043476A3 (en) Neuromedin s as a therapeutic agent
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
JP2013520405A5 (enExample)
JP2016510326A5 (enExample)
JP2013533268A5 (enExample)
JP2013503202A5 (enExample)
JP2015501329A5 (enExample)
RU2013110003A (ru) Комбинация соединений для лечения или предотвращения кожных заболеваний
JP2015512927A5 (enExample)
JP2016536357A5 (enExample)
JP2019528739A5 (enExample)
JP2011528334A5 (enExample)
WO2009046860A3 (en) Use of dago as a therapeutic agent
BR112014003529A2 (pt) combinações de corroles e estatinas
EP2231148A4 (en) Pharmaceutical composition for the treatment and prevention of heart disease
RU2010126662A (ru) Связывающие мср-1 нуклеиновые кислоты и их применение
JP2009532326A5 (enExample)
EA201290372A1 (ru) Композиция с замедленным высвобождением